甘李药业：2025年净利同比预增78.96%-95.23%

Core Viewpoint - Gannee Pharmaceutical (603087.SH) forecasts a net profit attributable to shareholders of 1.1 billion to 1.2 billion yuan for the fiscal year 2025, representing an increase of 78.96% to 95.23% compared to the previous year [1] Group 1: Financial Performance - The company expects significant growth in net profit due to increased domestic and international revenue [1] - Sales volume and revenue of insulin preparations have risen sharply, contributing to overall financial performance [1] - The transfer of a 55% stake in Jiangsu Gangan has generated investment income, further boosting net profit [1] Group 2: Strategic Developments - The company's internationalization strategy has shown positive results, enhancing its market presence [1]